Pharmacokinetic alterations in pregnancy and use of therapeutic drug monitoring;Médicaments et grossesse: modifications pharmacocinétiques et place du suivi thérapeutique pharmacologique

Therapie

Volumn 69, Issue 3, 2014, Pages 223-234

  Panchaud, Alice ^a,b   Weisskopf, Etienne ^b   Winterfeld, Ursula ^a   Baud, David ^a   Guidi, Monia ^b   Eap, Chin B ^b   Csajka, Chantal ^a,b   Widmer, Nicolas ^a,c  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c Clinical Pharmacy Pharmacie des Hôpitaux de l'Est Lémanique   (Switzerland)

Author keywords

Pharmacokinetics; Pregnancy; Teratogen; Therapeutic drug monitoring; Treatment outcome

Indexed keywords

ARTICLE; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; FETUS RISK; PHARMACOKINETICS; PREGNANCY; PRIORITY JOURNAL;

DRUG MONITORING; FEMALE; FETUS; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 84904336420     PISSN: 00405957     EISSN: 19585578     Source Type: Journal    
DOI: 10.2515/therapie/2014026     Document Type: Article

References (83)

1. Andrade SE, Gurwitz JH, Davis RL et al., Prescription drug use in pregnancy. Am J Obstet Gynecol 2004 Aug; 191 (2): 398-407
2. Piper JM, Baum C, Kennedy DL. Prescription drug use before and during pregnancy in a Medicaid population. Am J Obstet Gynecol 1987 Jul; 157 (1): 148-56
3. Mitchell AA, Gilboa SM, Werler MM et al., Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol 2011 Jul; 205 (1): 51 e1-8
4. Lupattelli A, Spigset O, Twigg MJ et al., Medication use during pregnancy: a cross-sectional, multinational web based study. BMJ Open 2014 Feb 17; 4 (2): e004365
5. Nordeng H, Ystrøm E, Einarson A. Perception of risk regarding the use of medications and other exposures during pregnancy. Eur J Clin Pharmacol 2010 Feb; 66 (2): 207-14
6. Widmer N, Csajka C, Werner D et al., Principles of therapeutic drug monitoring. Rev Med Suisse 2008 Jul 16; 4 (165): 1644-8
7. Widmer N, Werner D, Grouzmann E et al., Therapeutic drug monitoring: clinical practice. Rev Med Suisse 2008 Jul 16; 4 (165): 1649-50,. 1652-60
8. Loebstein R, Lalkin A, Koren G. Pharmacokinetic changes during pregnancy and their clinical relevance. Clin Pharmacokinet 1997 Nov; 33 (5): 328-43
9. Hodge LS, Tracy TS. Alterations in drug disposition during pregnancy: implications for drug therapy. Expert Opin Drug Metab Toxicol 2007 Aug; 3 (4): 557-71
10. Parry E, Shields R, Turnbull AC. Transit time in the small intestine in pregnancy. J Obstet Gynaecol Br Commonw 1970 Oct; 2 (10): 900-1
11. Chiloiro M, Darconza G, Piccioli E et al., Gastric emptying and orocecal transit time in pregnancy. J Gastroenterol 2001 Aug; 36 (8): 538-43
12. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. New Engl J Med 1998 Apr 16; 338 (16): 1128-37
13. Philipson A. Pharmacokinetics of ampicillin during pregnancy. J Infect Dis 1977 Sep; 136 (3): 370-6
14. Dawes M, Chowienczyk PJ. Drugs in pregnancy. Pharmacokinetics in pregnancy. Best Pract Res Clin Obstet Gynaecol 2001 Dec; 15 (6): 819-26
15. Mattison DR. Transdermal drug absorption during pregnancy. Clin Obstet Gynecol 1990 Dec; 33 (4): 718-27
16. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet 2005; 44 (10): 989-1008
17. Loebstein R, Koren G. Clinical relevance of therapeutic drug monitoring during pregnancy. Ther Drug Monit 2002; 24 (1): 15-22
18. Perucca E, Crema A. Plasma protein binding of drugs in pregnancy. Clin Pharmacokinet 1982 Jul-Aug; 7 (4): 336-52
19. Dean M, Stock B, Patterson RJ et al., Serum protein binding of drugs during and after pregnancy in humans. Clin Pharmacol Ther 1980 Aug; 28 (2): 253-61
20. Frederiksen MC. Physiologic changes in pregnancy and their effect on drug disposition. Semin Perinatol 2001 Jun; 25 (3): 120-3
21. Alexander EK, Marqusee E, Lawrence J et al., Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidism. New Engl J Med 2004 Jul 15; 351 (3): 241-9
22. Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002 Mar; 71 (3): 115-21
23. Davis M, Simmons CJ, Dordoni B et al., Induction of hepatic enzymes during normal human pregnancy. J Obstet Gynaecol Br Commonw 1973 Aug; 80 (8): 690-4
24. Nakai A, Sekiya I, Oya A et al., Assessment of the hepatic arterial and portal venous blood flows during pregnancy with Doppler ultrasonography. Arch Gynecol Obstet 2002 Jan; 266 (1): 25-9
25. Atkinson AJ, Abernethy DR, Daniels CE, et al. Principles of clinical pharmacology: Elsevier Inc. 2007
26. Tran TA, Leppik IE, Blesi K et al., Lamotrigine clearance during pregnancy. Neurology 2002 Jul 23; 59 (2): 251-5
27. McGready R, Stepniewska K, Edstein MD et al., The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. Eur J Clin Pharmacol 2003 Oct; 59 (7): 545-52
28. Prevost RR, Akl SA, Whybrew WD et al,. Oral nifedipine pharmacokinetics in pregnancy-induced hypertension. Pharmacotherapy 1992; 12 (3): 174-7
29. Pond SM, Kreek MJ, Tong TG et al., Altered methadone pharmacokinetics in methadone-maintained pregnant women. J Pharmacol Exp Ther 1985 Apr; 233 (1): 1-6
30. Ballabh P, Lo ES, Kumari J, Cooper TB et al., Pharmacokinetics of betamethasone in twin and singleton pregnancy. Clin Pharmacol Ther 2002 Jan; 71 (1): 39-45
31. Hutson JR, Koren G, Matthews SG. Placental P-glycoprotein and breast cancer resistance protein: influence of polymorphisms on fetal drug exposure and physiology. Placenta 2010 May; 31 (5): 351-7
32. Jeyabalan A, Conrad KP. Renal function during normal pregnancy and preeclampsia. Front Biosci 2007; 12: 2425-37
33. Duvekot JJ, Cheriex EC, Pieters FA et al., Early pregnancy changes in hemodynamics and volume homeostasis are consecutive adjustments triggered by a primary fall in systemic vascular tone. Am J Obstet Gynecol 1993 Dec; 169 (6): 1382-92
34. Matsui DM. Therapeutic drug monitoring in pregnancy. Ther Drug Monit 2012 Oct; 34 (5): 507-11
35. Knott C, Reynolds F. Therapeutic drug monitoring in pregnancy: rationale and current status. Clin Pharmacokinet 1990 Dec; 19 (6): 425-33
36. Winter ME, Tozer TN. Applied pharmacokinetics and pharmacodynamics: principles of therapeutic drug monitoring. In: Baltimore LWW, ed. 4th Ed ed. Baltimore 2006: 477
37. Parent X, Marzullo C, Gutbub AM. Valproic acid: a simple method for the estimation of free serum concentration. Ann Biol Clin (Paris) 1993; 51 (6): 649-50
38. DeVane CL, Stowe ZN, Donovan JL et al., Therapeutic drug monitoring of psychoactive drugs during pregnancy in the genomic era: challenges and opportunities. Psychopharmacol 2006 Jul; 20 (4 Suppl): 54-9
39. Deligiannidis KM. Therapeutic drug monitoring in pregnant and postpartum women: recommendations for SSRIs, lamotrigine, and lithium. J Clin Psychiatry 2010 May; 71 (5): 649-50
40. Hancock RL, Koren G, Einarson A et al., The effectiveness of teratology information services (TIS). Reprod Toxicol 2007 Feb; 23 (2): 125-32
41. Podsadecki TJ, Vrijens BC, Tousset EP et al., «White coat compliance» limits the reliability of therapeutic drug monitoring in HIV-1-infected patients. HIV Clinical Trials 2008 Jul-Aug; 9 (4): 238-46
42. Le Guellec C, Simon N, Hulot JS et al., Méthodologie pour l'évaluation du niveau de preuve du suivi thérapeutique pharmacologique. La Lettre du Pharmacologue 2009; 23 (1): 29-33
43. Roustit M, Jlaiel M, Leclercq P et al., Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women. Br J Clin Pharmacol 2008 Aug; 66 (2): 179-95
44. Asboe D, Aitken C, Boffito M et al., British HIV association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011. HIV Med 2012 Jan; 13 (1): 1-44
45. Solas C, Gagnieu MC, groupe suivi thérapeutique pharmacologique de la Societe francaise de pharmacologie et de thérapeutique. Evidence-based therapeutic drug monitoring for efavirenz. Therapie 2011 May-Jun; 2 (3): 197-205
46. Barrail-Tran A, Taburet AM, Poirier JM et al., Evidence-based therapeutic drug monitoring of lopinavir. Therapie 2011 May-Jun; 2 (3): 231-8
47. Roustit M, Jlaiel M, Leclercq P et al., Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women. Br J Clin Pharmacol 2008 Aug; 2 (2): 179-95
48. Fayet-Mello A, Buclin T, Guignard N et al,. Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant women. Antivir therapy 2013; 18 (2): 171-82
49. Stek AM, Mirochnick M, Capparelli E et al., Reduced lopinavir exposure during pregnancy. AIDS 2006 Oct 3; 2 (15): 1931-9
50. Lopez-Cortes LF, Ruiz-Valderas R, Rivero A et al., Efficacy of low-dose boosted saquinavir once daily plus nucleoside reverse transcriptase inhibitors in pregnant HIV-1-infected women with a therapeutic drug monitoring strategy. Ther Drug Monit 2007 Apr; 2 (2): 171-6
51. Goldberg HL. Psychotropic drugs in pregnancy and lactation. Int J Psychiatry Med 1994; 24 (2): 129-47
52. Cleary BJ, Butt H, Strawbridge JD et al., Medication use in early pregnancy-prevalence and determinants of use in a prospective cohort of women. Pharmacoepidemiol Drug Saf 2010 Apr; 2 (4): 408-17
53. Davalos DB, Yadon CA, Tregellas HC. Untreated prenatal maternal depression and the potential risks to offspring: a review. Arch Womens Ment Health 2012 Feb; 2 (1): 1-14
54. Grandjean EM, Aubry JM. Lithium: updated human knowledge using an evidence-based approach. Part II: Clinical pharmacology and therapeutic monitoring. CNS Drugs 2009; 23 (4): 331-49
55. Schou M, Amdisen A, Steenstrup OR. Lithium and pregnancy. II. Hazards to women given lithium during pregnancy and delivery. Br Med J 1973 Apr 21; 2 (5859): 137-8
56. Blake LD, Lucas DN, Aziz K et al., Lithium toxicity and the parturient: case report and literature review. Int J Obstet Anesth 2008 Apr; 2 (2): 164-9
57. Nishiwaki T, Tanaka K, Sekiya S. Acute lithium intoxication in pregnancy. Int J Gynaecol Obstet 1996 Feb; 2 (2): 191-2
58. Schaefer C, Spielmann H, Vetter K, et al. Arzneimittel in schwangerschaft und stillzeit. 8 ed: Urban & Fischer Verlag/Elsevier GmbH 2012
59. Nielsen RE, Damkier P. Pharmacological treatment of unipolar depression during pregnancy and breast-feeding - a clinical overview. Nord J psychiatry 2012 Jun; 2 (3): 159-66
60. Jonville-Béra AP, Vial T. Médicaments et grossesse: préscrire et évaluer le risque. Elsevier Masson, Issy les Moulineaux, France, 2012
61. Eggart V, Hiemke C, Zernig G. «There is no dose-response relationship in psychopharmacotherapy» vs «Pharmacotherapy in psychiatry is based on ligand-receptor interaction: a unifying hypothesis and the need for plasma concentration based clinical trials». Psychopharmacology (Berl) 2011 Sep; 2 (2): 297-300
62. Sit DK, Perel JM, Helsel JC et al., Changes in antidepressant metabolism and dosing across pregnancy and early postpartum. J Clin Psychiatry 2008 Apr; 2 (4): 652-8
63. Heikkinen T, Ekblad U, Kero P et al., Citalopram in pregnancy and lactation. Clin Pharmacol Ther 2002 Aug; 2 (2): 184-91
64. Freeman MP, Nolan PE Jr., Davis MF et al., Pharmacokinetics of sertraline across pregnancy and postpartum. J Clin Psychopharmacol 2008 Dec; 2 (6): 646-53
65. Heikkinen T, Ekblad U, Palo P et al., Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther 2003 Apr; 2 (4): 330-7
66. Ververs FF, Voorbij HA, Zwarts P et al., Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy. Clin Pharmacokinet 2009; 2 (10): 677-83
67. Hostetter A, Stowe ZN, Strader JR Jr. et al., Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications. Depress Anxiety 2000; 2 (2): 51-7
68. Hiemke C, Baumann P, Bergemann N et al., AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 2011 Sep; 2 (6): 195-235
69. Tomson T, Battino D. Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium. Clin Pharmacokinet 2007; 2 (3): 209-19
70. Tomson T, Landmark CJ, Battino D. Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications. Epilepsia 2013 Mar; 2 (3): 405-14
71. Sabers A, Tomson T. Managing antiepileptic drugs during pregnancy and lactation. Curr Opinion Neurol 2009 Apr; 2 (2): 157-61
72. Harden CL, Pennell PB, Koppel BS et al., Management issues for women with epilepsy - focus on pregnancy (an evidence-based review): III. Vitamin K, folic acid, blood levels, and breast-feeding: report of the quality standards subcommittee and therapeutics and technology assessment subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009 May; 2 (5): 1247-55
73. Ohman I, Beck O, Vitols S et al., Plasma concentrations of lamotrigine and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy. Epilepsia 2008 Jun; 2 (6): 1075-80
74. Pennell PB, Peng L, Newport DJ et al., Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. Neurology 2008 May 27; 70 (22 Pt 2): 2130-6
75. Sabers A. Algorithm for lamotrigine dose adjustment before, during, and after pregnancy. Acta Neurol Scand 2012 Jul; 126 (1): e1-4
76. Tomson T, Palm R, Kallen K et al., Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. Epilepsia 2007 Jun; 2 (6): 1111-6
77. Westin AA, Reimers A, Helde G et al., Serum concentration/dose ratio of levetiracetam before, during and after pregnancy. Seizure 2008 Mar; 2 (2): 192-8
78. Muret P, Solas C, groupe suivi thérapeutique pharmacologique de la Société française de pharmacologie et de thérapeutique. Niveau de preuve du suivi thérapeutique pharmacologique du saquinavir. Therapie 2011 Mai-Juin; 2 (3): 207-12
79. Muret P, Piedoux S, Solas C et al., Niveau de preuve du suivi thérapeutique pharmacologique de la névirapine. Therapie 2011 Mai-Juin; 2 (3): 187-95
80. Tomson T, Dahl ML, Kimland E. Therapeutic monitoring of antiepileptic drugs for epilepsy. The Cochrane database Syst Rev 2007 Jan 24 (1): CD002216
81. Patsalos PN, Berry DJ, Bourgeois BF et al., Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008 Jul; 2 (7): 1239-76
82. Bentue-Ferrer D, Verdier MC, Tribut O. Suivi thérapeutique pharmacologique de la primidone et du phénobarbital. Therapie 2012 Juil-Aou; 2 (4): 381-90
83. Bentue-Ferrer D, Tribut O, Verdier MC et al., Suivi thérapeutique pharmacologique de la lamotrigine. Therapie 2010 Jan-Fev; 2 (1): 39-46